19 withdrawn. 19 Phase 3, 3 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 19 | Withdrawn 19 |
| Phase 2 | 3 | Withdrawn 3 |
Follow Gastroenteritis: new trials by email Literature Review of Gastroenteritis trials Research Report on Gastroenteritis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Assess Adverse Events and Change in Disease Condition of Mesalamine Capsules in Children Aged 5 to 17 Years With Ulcerative Colitis Mesalamine, Placebo - Ulcerative Colitis (UC) | Phase 3 | Withdrawn | AbbVie | 2025-09-15 | 2025-08-12 | |
| SAVES-IBD: Safety & Efficacy of Aspirin vs. Standard of Care for VTE Prophylaxis After IBD Surgery Aspirin 81Mg Ec Tab, Standard of Care - Crohn Disease, Ulcerative Colitis | Phase 3 | Withdrawn | Stefan Holubar MD MS FACS, FASCRS | 2024-06-01 | 2024-04-18 | |
| Phase 2b/3 Study of ABX464 in Moderate to Severe Active Crohn's Disease Patients ABX464, Placebo - Crohn Disease | Phase 2 / Phase 3 | Withdrawn | Abivax S.A. | 2022-09-19 | 2024-07-31 | |
| A Study to Assess Subcutaneous AK002 in Eosinophilic Gastritis and/or Eosinophilic Duodenitis AK002, Placebo - Eosinophilic Gastritis, Eosinophilic Duodenitis | Phase 3 | Withdrawn | Allakos Inc. | 2021-12-01 | 2023-03-03 | |
| A Study to Test Efficacy, Safety, and Pharmacokinetics of Certolizumab Pegol in Children and Adolescents With Moderately to Severely Active Crohn's Disease Certolizumab pegol, Adalimumab, Placebo - Crohn's Disease | Phase 3 | Withdrawn | UCB Biopharma SRL | 2021-06-01 | 2021-06-23 | |
| A Study of Mirikizumab (LY3074828) in Participants With Ulcerative Colitis Mirikizumab IV, Mirikizumab SC, Vedolizumab IV - Ulcerative Colitis | Phase 3 | Withdrawn | Eli Lilly and Company | 2021-04-20 | 2021-05-06 | |
| Curcumin in Pediatric Ulcerative Colitis Curcumin, Placebo - Ulcerative Colitis | Phase 3 | Withdrawn | Schneider Children's Medical Center, Israel | 2020-03-01 | 2021-10-01 | |
| Cannabidiol Usage as an Adjunct Therapy for Crohn's Disease Cannabidiol, Placebo oral capsule - Crohn Disease, Inflammatory Bowel Diseases | Phase 2 / Phase 3 | Withdrawn | University of Illinois at Chicago | 2018-07-01 | 2020-03-25 | |
| A Study of Efficacy and Safety of Mongersen (GED-0301) for the Treatment of Adult and Adolescent Subjects With Active Crohn's Disease GED-0301, Placebo - Crohn Disease | Phase 3 | Withdrawn | Celgene | 2017-12-01 | 2017-11-14 | |
| Efficacy and Safety of Vedolizumab Intravenous (IV) in the Treatment of Primary Sclerosing Cholangitis in Subjects With Underlying Inflammatory Bowel Disease Vedolizumab, Placebo - Primary Sclerosing Cholangitis, Inflammatory Bowel Disease | Phase 3 | Withdrawn | Takeda | 2017-02-01 | 2017-03-08 | |
| Managing Infliximab Reinduction After Temporary Discontinuation of Drug Infliximab at weeks 0,2, and 6, Infliximab at weeks 0,4, and 8, Infliximab at weeks 0 and 8 - Inflammatory Bowel Disease | Phase 3 | Withdrawn | NYU Langone Health | 2016-07-01 | 2016-06-30 | |
| The Efficacy of Topical Mesalazine Sustained-Release Tablets in Crohn's Disease Patients With Oral Ulcer Mesalazine Sustained-Release Tablets, Riboflavin Sodium Phosphate Injection - Crohn's Disease, Oral Ulcer | Phase 3 | Withdrawn | Xijing Hospital of Digestive Diseases | 2016-03-01 | 2023-02-01 | |
| Calprotectin-Directed Humira® Maintenance Therapy (CADHUM) Adalimumab, Adalimumab PRN, Placebo - Crohn's Disease | Phase 3 | Withdrawn | Peter Higgins | 2013-10-01 | 2017-05-24 | |
| Eosinophilic Esophagitis Treatment: Montelukast vs Fluticasone Montelukast, Fluticasone - Eosinophilic Esophagitis, Dysphagia | Phase 3 | Withdrawn | Medical College of Wisconsin | 2012-01-01 | 2019-08-28 | |
| Ketamine and Hydromorphone for Patient Controlled Pain Relief in Children's Mucositis Ketamine & hydromorphone - Mucositis | Phase 3 | Withdrawn | University of British Columbia | 2009-08-01 | 2010-11-01 | |
| A Trial Evaluating Safety of Chronic Therapy With Certolizumab Pegol in Crohn's Disease Certolizumab pegol - Crohn's Disease | Phase 3 | Withdrawn | UCB Pharma | 2007-11-01 | 2012-05-28 | |
| Evaluate Efficacy of Certolizumab in Crohn's Patients With Draining Fistulas Certolizumab pegol - Crohn Disease | Phase 3 | Withdrawn | UCB Pharma | 2007-01-01 | 2012-05-28 | |
| A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Visilizumab in Subjects With Intravenous Steroid-Refractory Ulcerative Colitis Visilizumab (HuM291; Nuvion®) - Intravenous Steroid-Refractory Ulcerative Colitis | Phase 3 | Withdrawn | Facet Biotech | 150 | 2009-06-25 | |
| Retarded Phosphatidylcholine Versus Mesalazin in Remission of Ulcerative Colitis. retarded release phosphatidylcholine - Ulcerative Colitis | Phase 2 / Phase 3 | Withdrawn | Heidelberg University | 2013-12-13 |
Crohn Disease (9) · Colitis, Ulcerative (6) · Inflammatory Bowel Diseases (4) · Eosinophilic Esophagitis (2) · Cholangitis, Sclerosing (1) · Deglutition Disorders (1) · Eosinophilic enteropathy (1) · Fistula (1) · Marijuana Abuse (1) · Mucositis (1) · Oral Ulcer (1) · Recurrence (1) · Venous Thromboembolism (1)
Digestive System Diseases (19) · Gastrointestinal Diseases (19) · Intestinal Diseases (16) · Inflammatory Bowel Diseases (12) · Colitis (6) · Colonic Diseases (6) · Eosinophilia (2) · Esophageal Diseases (2) · Esophagitis (2) · Hematologic Diseases (2) · Hemic and Lymphatic Diseases (2) · Hypersensitivity (2) · Hypersensitivity, Immediate (2) · Immune System Diseases (2)
Certolizumab Pegol (3) · Adalimumab (2) · Mesalamine (2) · ABX464 (1) · AK002 (1) · Aspirin (1) · Cannabidiol (1) · Cannabinoids (1) · Curcumin (1) · Flavin Mononucleotide (1) · Fluticasone (1) · GED0301 (1) · Hydromorphone (1) · Ketamine (1) · Standard of Care (1)
UCB Pharma (2) · AbbVie (1) · Abivax S.A. (1) · Allakos Inc. (1) · Celgene (1) · Eli Lilly and Company (1) · Facet Biotech (1) · Heidelberg University (1) · Medical College of Wisconsin (1) · NYU Langone Health (1) · Peter Higgins (1) · Schneider Children's Medical Center, Israel (1) · Stefan Holubar MD MS FACS, FASCRS (1) · Takeda (1) · UCB Biopharma SRL (1)
United States (6) · Belgium (2) · Canada (2) · Germany (2) · Israel (2) · Australia (1) · Austria (1) · China (1) · Croatia (1) · Czechia (1) · Denmark (1) · Finland (1) · France (1) · Greece (1) · Hungary (1)
Amit Assa, MD (1) · Carolyne Montgomery, MD (1) · Caron Strahlendorf, MD (1) · Colleen Court, MD (1) · Craig Paterson, MD (1) · Denesh Chitkara, MD (1) · George Syrmalis, M.D. M.Sc. Ph.D. (1) · Joanne Lim (1) · Krassimir Mitchev, MD (1) · Lea Chen (1) · Mark Ansermino, MD (1) · Nikhil Shastri, MD (1)
2014 (1), 2019 (1)